Nabriva Therapeutics plc

Equities

NBRVF

IE000OZRGNV6

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:14:56 2024-07-09 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	+9,900.00%

2023	Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
2023	Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index	CI

NABRIVA THERAPEUTICS PLC : Other Events (form 8-K)

January 14, 2022 at 04:18 pm EST

Item 8.01. Other Events.

On January 14, 2022, Nabriva Therapeutics plc (the "Company") announced that it adjourned, without conducting any business, the Company's extraordinary general meeting of shareholders (the "EGM"), on Friday, January 14, 2022 until Tuesday, January 18, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021. The record date for the EGM continues to be the close of business on November 19, 2021.

Latest news about Nabriva Therapeutics plc

Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-10-19	CI
Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index	23-07-31	CI
Sumitomo Pharma Co., Ltd. acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.	23-07-30	CI
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer	23-07-10	MT
Nabriva Therapeutics plc Appoints H. Michael Hogan as Chief Executive Officer	23-07-07	CI
Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer	23-07-07	CI
Nabriva Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Nabriva Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Nabriva Therapeutics plc Auditor Raises 'Going Concern' Doubt	23-04-16	CI
Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer	23-01-20	CI
Health Care Up as Biogen Rises on Alzheimer's Drug Progress -- Health Care Roundup	23-01-06	DJ
Sector Update: Healthcare Stocks Rise Friday, Mostly Trail Other Sectors	23-01-06	MT
Top Midday Decliners	23-01-06	MT
Sector Update: Health Care Stocks Posting Moderate Advance Friday Afternoon	23-01-06	MT
Sector Update: Health Care Stocks Gain Premarket Friday	23-01-06	MT
December Jobs Report Showing Easing Wage Pressures Lift US Equity Futures	23-01-06	MT
Nabriva Therapeutics Approves Wind-Down Plan, Will Terminate All Non-Essential Employees; Shares Fall Pre-Bell	23-01-06	MT
Top Premarket Decliners	23-01-06	MT
Nabriva Says Phase 1 Trial of Cystic Fibrosis Drug Candidate Shows Safety Profile in Line With Prior Studies in Healthy Subjects	22-11-28	MT
Nabriva Therapeutics plc Announces Positive Topline Results from Phase 1 Trial of XENLETA in Adult Patients with Cystic Fibrosis	22-11-28	CI
Transcript : Nabriva Therapeutics plc, Q3 2022 Earnings Call, Nov 10, 2022	22-11-10
Nabriva Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Earnings Flash (NBRV) NABRIVA THERAPEUTICS Reports Q3 Revenue $9.2M	22-11-10	MT
Earnings Flash (NBRV) NABRIVA THERAPEUTICS Posts Q3 Loss $-4.21	22-11-10	MT
Wall Street Set to Open Mixed as Jobless Report Better Than Expected	22-09-15	MT

Chart Nabriva Therapeutics plc

Duration

Period

More charts

Company Profile

Nabriva Therapeutics PLC is a biopharmaceutical company. The Company is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum Î²-lactamase-, or ESBL-producing Enterobacteriaceae.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
NABRIVA THERAPEUTICS PLC	+9,900.00%	323
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs